13 completed, 2 terminated, 1 active not recruiting. 8 Phase 3, 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 6, Active not recruiting 1, Terminated 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow anacetrapib: new trials by email Literature Review of anacetrapib trials Research Report on anacetrapib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Anacetrapib on Vascular Function and Arterial Stiffness Anacetrapib, Statin, Placebo - Atherosclerotic Cardiovascular Disease, Vascular Disease | Completed | Cambridge University Hospitals NHS Foundation Trust | 103 | 2017-01-01 | 2024-02-07 | |
| Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 2 | 2013-06-01 | 2015-06-01 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) Anacetrapib, Placebo - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 589 | 2013-05-13 | 2020-05-29 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) Anacetrapib, Placebo for anacetrapib - Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Completed | Merck Sharp & Dohme LLC | 68 | 2013-05-01 | 2016-04-25 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1) Anacetrapib, Placebo for anacetrapib - Dyslipidemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 307 | 2013-03-14 | 2017-06-01 |
| A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021) Anacetrapib 100 mg, Placebo for anacetrapib 100 mg, Anacetrapib 25 mg - Hypercholesterolemia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 459 | 2012-11-06 | 2017-04-17 |
| Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Anacetrapib, Placebo - Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial | Phase 3 | Completed | Merck Sharp & Dohme LLC | 306 | 2012-02-03 | 2019-10-14 |
| REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification Anacetrapib, Placebo anacetrapib - Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | University of Oxford | 30449 | 2011-06-01 | 2024-06-25 |
| Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038) anacetrapib - Dyslipidemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2010-06-01 | 2015-08-14 |
| Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039) anacetrapib - Dyslipidemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2010-05-01 | 2015-10-14 |
| The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3) anacetrapib, Comparator: atorvastatin, Comparator: placebo to MK0859 - Dyslipidemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 46 | 2009-11-01 | 2015-06-04 |
| A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) anacetrapib, Comparator: atorvastatin, Comparator: Placebo - Dyslipidemia | Phase 2 | Completed | Merck Sharp & Dohme LLC | 408 | 2009-09-01 | 2015-05-06 |
| Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019) anacetrapib, Comparator: placebo - Coronary Heart Disease (CHD), CHD Risk-Equivalent Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1623 | 2008-03-24 | 2017-12-11 |
| A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED) MK0859 - Hypercholesterolemia, Hyperlipidemia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 50 | 2006-07-01 | 2015-02-25 |
| A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED) MK0859 - Ambulatory Blood Pressure | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2006-07-01 | 2015-02-27 |
| MK0859 Dose-Ranging Study (0859-003) MK0859 - Hypercholesterolemia, Mixed Hyperlipemia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 500 | 2006-06-01 | 2015-03-02 |
Dyslipidemias (5) · Hypercholesterolemia (4) · Atherosclerosis (2) · Hyperlipoproteinemia Type II (2) · Inhibition, Psychological (2) · Vascular Diseases (2) · Cardiovascular Diseases (1) · Coronary Disease (1) · Hepatic Insufficiency (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type V (1) · Renal Insufficiency (1)
Merck Sharp & Dohme LLC (14) · Cambridge University Hospitals NHS Foundation Trust (1) · University of Oxford (1)
United Kingdom (2)
Joseph Cheriyan, MBChB, MA, FRCP (1) · Louise Bowman (1) · Martin Landray (1)
PMID 18068514, PMID 24782116, PMID 19781408, PMID 21082868, PMID 21982664, PMID 22180633, PMID 22696435, PMID 23958252, PMID 24737712, PMID 25670362, PMID 25670366, PMID 27131642, PMID 27956003, PMID 28478132, PMID 28624096, PMID 28729361, PMID 28847206, PMID 31331193, PMID 34910136, PMID 37750555, PMID 41843779